

ITL Orders 1000 Felix™ Cartridges Across Existing and New MENA Markets as Regional Demand Accelerates

Highlights

- Memphasys receives an additional order from International Technical Legacy (ITL) for 1,000 Felix™ cartridges.
- Hamad Medical Corporation (HMC), Qatar's largest IVF institution, continues its repeat cartridge order program and has separately ordered a second Felix™ console - a clear signal of institutional commitment to Felix™ as a clinical standard¹
- Order also covers new markets including The United Arab Emirates (UAE) and Kuwait following initial evaluations.
- Additional orders to meet Turkish demand are expected in July, pending regulatory approval of the Felix™ System by local authorities. Six local commercial partners appointed recently working directly with ITL and Memphasys to accelerate sales across UAE, Kuwait, Turkey, Egypt, Bahrain and Jordan to drive further demand across the Middle East and North Africa region.
- Confirmed ITL orders have now reached 1,800 Felix™ of the distributor's 2,500-cartridge annual minimum commitment cartridges in less than two quarters following CE Mark approval.
- 400 cartridges to be dispatched immediately to meet demand in Qatar, UAE and Kuwait, with a further 600 confirmed in October 2026.

Memphasys Limited (ASX: MEM) ("Memphasys" or "the Company") is pleased to announce that International Technical Legacy (ITL), its exclusive Middle East and North Africa (MENA) commercialisation partner, has placed an order for 1,000 Felix™ cartridges.

The order reflects a significant broadening and deepening of commercial activity across the MENA. At its centre is Hamad Medical Corporation (HMC) - Qatar's primary public health provider and the Company's anchor institutional reference customer - which is not only placing continued repeat cartridge orders but has separately ordered a second Felix™ console.

The decision by HMC to invest in a second console is a meaningful commercial signal. It reflects institutional intent to scale Felix™ utilisation across HMC's treatment program, effectively doubling throughput capacity and cementing Felix™ as a standard-of-care sperm preparation platform at Qatar's largest fertility institution.

¹ Refer ASX announcement dated 2 February 2026

Order Composition: Growing Demand Across Existing and New MENA Markets

The 1,000-cartridge order from ITL reflects growing demand across both established and emerging markets, while also supporting expansion into new territories.

The order includes 400 cartridges for:

- **Qatar:** Continued repeat orders for HMC's ongoing clinical program, which commenced in early 2026² and includes at least one new clinic from Qatar that will commence using Felix™.
- **UAE:** Repeat orders following successful initial evaluations, reflecting conversion from trial use to committed procurement.
- **Kuwait:** Repeat orders following successful initial evaluations, reflecting conversion from trial use to committed procurement.

Further 600-cartridge order confirmed for October 2026 to meet the demand from the existing clients.

Together, these orders confirm that Felix™ demand within the ITL network is broadening well beyond a single anchor site and accelerating across the region. This accelerated order trajectory provides Memphasys with strong early validation of recurring commercial demand across the MENA region and reinforces the Company's confidence in the scalability of the ITL partnership, contracted revenue visibility and ongoing cashflow planning. The Company expects additional Felix orders to meet ongoing demand for these regions throughout 2026.

Turkey and Other MENA Markets: Imminent Regulatory Registration and Orders

Turkey was added to the ITL distribution agreement as a territory following CE Mark approval and the contract upgrade in September 2025³. With local regulatory registration expected imminently, orders from Turkey will commence in July, followed by other markets such as Egypt, Bahrain and Jordan later in the year.

Marjan Mikel, Chair of the Memphasys Commercialisation Committee, commented:

"This order demonstrates what genuine clinical adoption looks like in practice. HMC ordering a second console tells you everything about the strength of the clinical experience. And with UAE and Kuwait, joining we are seeing exactly the region-wide network effect that the ITL partnership was designed to generate. ITL is tracking well and the pipeline across the MENA network continues to grow."

Outlook

With this order, Memphasys and ITL are delivering on the commercial thesis underpinning the MENA exclusive distribution agreement - disciplined, clinic-by-clinic adoption that compounds into durable recurring revenue. Key near-term catalysts include:

- Dispatch of the 400-cartridge order
- Imminent Turkish regulatory registration, expected to unlock additional Felix™ sales in 2026, followed by other key MENA markets

² Refer ASX announcement dated 2 February 2026

³ Refer ASX announcement dated 18 September 2025

- Continued HMC scaling, with the second console expected to increase Felix™ throughput capacity at Qatar’s largest fertility institution and a new clinic commencing to use the technology
- Ongoing pipeline development across ITL’s network
- 600 cartridges to be delivered in October 2026.

The Company is in advanced contract negotiations with several prospective new clients and partners across both new and existing jurisdictions, and looks forward to updating the market in due course.

Authorised by the Board of Memphasys Limited.

Ends

For further information, please contact:

Colin Jacoby

Chapter One Advisors

Tel: +61 439 980 359

E: cjacoby@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction.

By combining electrophoresis and size-exclusion membranes, Felix™ delivers a fast, gentle and standardised sperm selection process that enhances sperm quality and reduces laboratory time. The system replaces traditional centrifugation, which can cause cellular stress and DNA damage, offering clinicians a superior, repeatable alternative.

Memphasys’ commercial strategy focuses on building contracted sales through direct and distribution-led channels, scaling production to improve margins, and establishing Felix™ as a new global standard in sperm preparation for ART procedures.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Memphasys’s current expectations, estimates and projections about the industry in which Memphasys operates, and its beliefs and assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties and are not guarantees of future performance. Memphasys cautions shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Memphasys only as of the date of this release.